Concentra Group Holdings Parent, Inc.
Concentra Group Holdings Parent, Inc. (CON) Stock Competitors & Peer Comparison
See (CON) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Equipment & Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CON | $22.56 | -0.49% | 2.9B | 17.49 | $1.29 | +1.11% |
| SIRO | $109.97 | +0.00% | 22B | N/A | N/A | N/A |
| HIMS | $27.91 | -5.04% | 6.1B | 54.76 | $0.51 | N/A |
| NVST | $26.49 | -1.05% | 4.3B | 94.63 | $0.28 | N/A |
| BBNX | $10.08 | -5.35% | 449.2M | -7.36 | -$1.37 | N/A |
| CV | $6.78 | +6.44% | 337.9M | -6.58 | -$1.03 | N/A |
| NAKA | $0.19 | -4.42% | 70M | -0.72 | -$0.26 | N/A |
| KDLY | $11.30 | +1.16% | 68.1M | -15.48 | -$0.73 | N/A |
| NEUE | $6.75 | +0.00% | 60.9M | -0.38 | -$17.65 | N/A |
| PARK | $17.75 | -2.58% | 34.7M | -99.11 | -$0.18 | N/A |
Stock Comparison
CON vs SIRO Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, SIRO has a market cap of 22B. Regarding current trading prices, CON is priced at $22.56, while SIRO trades at $109.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas SIRO's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to SIRO's ROE of +0.14%. Regarding short-term risk, CON is more volatile compared to SIRO. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check SIRO's competition here
CON vs HIMS Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, HIMS has a market cap of 6.1B. Regarding current trading prices, CON is priced at $22.56, while HIMS trades at $27.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas HIMS's P/E ratio is 54.76. In terms of profitability, CON's ROE is +0.47%, compared to HIMS's ROE of +0.23%. Regarding short-term risk, CON is less volatile compared to HIMS. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check HIMS's competition here
CON vs NVST Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, NVST has a market cap of 4.3B. Regarding current trading prices, CON is priced at $22.56, while NVST trades at $26.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas NVST's P/E ratio is 94.63. In terms of profitability, CON's ROE is +0.47%, compared to NVST's ROE of +0.02%. Regarding short-term risk, CON is more volatile compared to NVST. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check NVST's competition here
CON vs BBNX Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, BBNX has a market cap of 449.2M. Regarding current trading prices, CON is priced at $22.56, while BBNX trades at $10.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas BBNX's P/E ratio is -7.36. In terms of profitability, CON's ROE is +0.47%, compared to BBNX's ROE of -0.23%. Regarding short-term risk, CON is less volatile compared to BBNX. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check BBNX's competition here
CON vs CV Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, CV has a market cap of 337.9M. Regarding current trading prices, CON is priced at $22.56, while CV trades at $6.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas CV's P/E ratio is -6.58. In terms of profitability, CON's ROE is +0.47%, compared to CV's ROE of +1.05%. Regarding short-term risk, CON is less volatile compared to CV. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check CV's competition here
CON vs NAKA Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, NAKA has a market cap of 70M. Regarding current trading prices, CON is priced at $22.56, while NAKA trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas NAKA's P/E ratio is -0.72. In terms of profitability, CON's ROE is +0.47%, compared to NAKA's ROE of -0.21%. Regarding short-term risk, CON is less volatile compared to NAKA. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check NAKA's competition here
CON vs KDLY Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, KDLY has a market cap of 68.1M. Regarding current trading prices, CON is priced at $22.56, while KDLY trades at $11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas KDLY's P/E ratio is -15.48. In terms of profitability, CON's ROE is +0.47%, compared to KDLY's ROE of -0.21%. Regarding short-term risk, CON is less volatile compared to KDLY. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check KDLY's competition here
CON vs NEUE Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, NEUE has a market cap of 60.9M. Regarding current trading prices, CON is priced at $22.56, while NEUE trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas NEUE's P/E ratio is -0.38. In terms of profitability, CON's ROE is +0.47%, compared to NEUE's ROE of +0.09%. Regarding short-term risk, CON is more volatile compared to NEUE. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check NEUE's competition here
CON vs PARK Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, PARK has a market cap of 34.7M. Regarding current trading prices, CON is priced at $22.56, while PARK trades at $17.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas PARK's P/E ratio is -99.11. In terms of profitability, CON's ROE is +0.47%, compared to PARK's ROE of -67.96%. Regarding short-term risk, CON is less volatile compared to PARK. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check PARK's competition here
CON vs BRK Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, BRK has a market cap of 11.6M. Regarding current trading prices, CON is priced at $22.56, while BRK trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas BRK's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to BRK's ROE of N/A. Regarding short-term risk, CON is more volatile compared to BRK. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check BRK's competition here
CON vs PFSA Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, PFSA has a market cap of 309.2K. Regarding current trading prices, CON is priced at $22.56, while PFSA trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas PFSA's P/E ratio is -0.01. In terms of profitability, CON's ROE is +0.47%, compared to PFSA's ROE of +0.82%. Regarding short-term risk, CON is less volatile compared to PFSA. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check PFSA's competition here
CON vs DSCI Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, DSCI has a market cap of 0. Regarding current trading prices, CON is priced at $22.56, while DSCI trades at $7.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas DSCI's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to DSCI's ROE of -0.00%. Regarding short-term risk, CON is more volatile compared to DSCI. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check DSCI's competition here
CON vs LPNT Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, LPNT has a market cap of 0. Regarding current trading prices, CON is priced at $22.56, while LPNT trades at $64.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas LPNT's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to LPNT's ROE of +0.05%. Regarding short-term risk, CON is more volatile compared to LPNT. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check LPNT's competition here
CON vs AMSG Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, AMSG has a market cap of 0. Regarding current trading prices, CON is priced at $22.56, while AMSG trades at $67.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas AMSG's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to AMSG's ROE of +0.08%. Regarding short-term risk, CON is less volatile compared to AMSG. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check AMSG's competition here
CON vs ABAX Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, ABAX has a market cap of 0. Regarding current trading prices, CON is priced at $22.56, while ABAX trades at $83.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas ABAX's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to ABAX's ROE of +0.10%. Regarding short-term risk, CON is more volatile compared to ABAX. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check ABAX's competition here
CON vs MEDC Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, MEDC has a market cap of 0. Regarding current trading prices, CON is priced at $22.56, while MEDC trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas MEDC's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to MEDC's ROE of N/A. Regarding short-term risk, CON is less volatile compared to MEDC. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check MEDC's competition here
CON vs COTV Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, COTV has a market cap of 0. Regarding current trading prices, CON is priced at $22.56, while COTV trades at $44.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas COTV's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to COTV's ROE of +0.14%. Regarding short-term risk, CON is more volatile compared to COTV. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check COTV's competition here
CON vs EVHC Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, EVHC has a market cap of 0. Regarding current trading prices, CON is priced at $22.56, while EVHC trades at $45.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas EVHC's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to EVHC's ROE of +0.07%. Regarding short-term risk, CON is more volatile compared to EVHC. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check EVHC's competition here
CON vs CYNO Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, CYNO has a market cap of 0. Regarding current trading prices, CON is priced at $22.56, while CYNO trades at $66.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas CYNO's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to CYNO's ROE of +0.03%. Regarding short-term risk, CON is more volatile compared to CYNO. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check CYNO's competition here
CON vs SPAN Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, SPAN has a market cap of 0. Regarding current trading prices, CON is priced at $22.56, while SPAN trades at $29.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas SPAN's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to SPAN's ROE of +0.17%. Regarding short-term risk, CON is less volatile compared to SPAN. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check SPAN's competition here
CON vs EXAC Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, EXAC has a market cap of 0. Regarding current trading prices, CON is priced at $22.56, while EXAC trades at $49.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas EXAC's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to EXAC's ROE of +0.00%. Regarding short-term risk, CON is more volatile compared to EXAC. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check EXAC's competition here
CON vs SCAI Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, SCAI has a market cap of 0. Regarding current trading prices, CON is priced at $22.56, while SCAI trades at $55.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas SCAI's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to SCAI's ROE of +0.09%. Regarding short-term risk, CON is more volatile compared to SCAI. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check SCAI's competition here
CON vs LDR Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, LDR has a market cap of 0. Regarding current trading prices, CON is priced at $22.56, while LDR trades at $67.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas LDR's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to LDR's ROE of +1.17%. Regarding short-term risk, CON is more volatile compared to LDR. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check LDR's competition here
CON vs ABCO Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, ABCO has a market cap of 0. Regarding current trading prices, CON is priced at $22.56, while ABCO trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas ABCO's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to ABCO's ROE of +0.19%. Regarding short-term risk, CON is more volatile compared to ABCO. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check ABCO's competition here
CON vs SPNC Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, SPNC has a market cap of 0. Regarding current trading prices, CON is priced at $22.56, while SPNC trades at $38.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas SPNC's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to SPNC's ROE of -0.61%. Regarding short-term risk, CON is more volatile compared to SPNC. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check SPNC's competition here
CON vs MZOR Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, MZOR has a market cap of 0. Regarding current trading prices, CON is priced at $22.56, while MZOR trades at $58.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas MZOR's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to MZOR's ROE of -0.14%. Regarding short-term risk, CON is more volatile compared to MZOR. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check MZOR's competition here
CON vs PMC Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, PMC has a market cap of 0. Regarding current trading prices, CON is priced at $22.56, while PMC trades at $29.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas PMC's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to PMC's ROE of +0.04%. Regarding short-term risk, CON is more volatile compared to PMC. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check PMC's competition here
CON vs STJ Comparison April 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 2.9B. In comparison, STJ has a market cap of 0. Regarding current trading prices, CON is priced at $22.56, while STJ trades at $80.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 17.49, whereas STJ's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.47%, compared to STJ's ROE of +0.21%. Regarding short-term risk, CON is more volatile compared to STJ. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check STJ's competition here